መነሻ › ፕሌክሲፎርም ኒውሮፋይብሮማ › ሜሪላንድ
በሜሪላንድ ለፕሌክሲፎርም ኒውሮፋይብሮማ የሚደረጉ ክሊኒካዊ ጥናቶች
ለፕሌክሲፎርም ኒውሮፋይብሮማ የሚደረጉ 6 ጥናቶች በሜሪላንድ ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
Official study text (English)
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
- National Institutes of Health Clinical Center, Bethesda
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናትጤናማ ተሳታዮች ይቀበላሉ
እድሜ 5 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT02544022Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)
- National Institutes of Health Clinical Center, Bethesda
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ ከ3 እስከ 120 · ሁሉም ጾታዎች · የተሻሻለው በ2 ሴፕቴ 2026 · NCT06222203Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- National Institutes of Health Clinical Center, Bethesda
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ ከ3 እስከ 35 · ሁሉም ጾታዎች · የተሻሻለው በ24 ኦገስ 2026 · NCT02390752A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
- Johns Hopkins Hospital, Baltimore
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ29 ጁላይ 2026 · NCT06541847A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)
- National Institutes of Health Clinical Center, Bethesda
ተሳታዮችን በመፈለግ ላይ
እድሜ ከ1 እስከ 120 · ሁሉም ጾታዎች · የተሻሻለው በ9 ጁን 2026 · NCT06507748Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
- Johns Hopkins University, Baltimore
- National Cancer Institute/ National Institutes of Health, Bethesda
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ1 እስከ 8 · ሁሉም ጾታዎች · የተሻሻለው በ29 ሜይ 2026 · NCT06188741ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።